|   |   |
   Home  |  Site Map  |  Contact Us  

Over the next decade, nanotechnology has the potential to influence virtually every aspect of our lives, including our energy, food, water, buildings, and medicines. However, in order to realize this broad potential - robust, cost-effective, regulatory-friendly manufacturing technologies will be required. Through its novel technology platform and expansive intellectual property, Liquidia is poised to be a leader in the development of nanotechnology-based healthcare products and a catalyst for the growth anticipated across this industry.

By leveraging fabrication techniques from the semiconductor industry, Liquidia has the ability to rapidly design and manufacture precisely engineered particles of virtually any size, shape, or composition. Learn more >


November 12, 2013
Envisia Therapeutics Debuts with $25 Million Series A Financing Details

September 30, 2013
Liquidia Technologies to present at ACS Polymers in Medicine and Biology 2013 Conference Oct 9-13, 2013 Details

June 25, 2013
Liquidia Technologies Appoints Timothy Albury as Chief Financial Officer Details

May 21, 2013
Liquidia announces Extension of Collaboration with PATH to Develop Next Generation Pneumococcal Vaccine Details

May 15, 2013
Liquidia Technologies CMO Frank Malinoski, MD, PhD, elected Vice Chair of Nanomedicines Alliance Details




November 13, 2013
Fierce Drug Delivery: : Sustained-Release Glaucoma Treatment nets $25M for Liquidia's Envisia Details

November 12, 2013
N&O: Envisia Therapeutics Launches with $25 Million in Financing Details

August 29, 2013
Liquidia Technologies Finalist for 2013 NCTA 21 Award Details

July 10, 2013
Customizable Nanoparticle Technologies Offer Look into the Future of Drug Delivery Details

May 3, 2013
Reuters: Big Drugmakers Think Small with Nanomedicine Deals Details

© 2013 Liquidia Technologies | PO Box 110085 | Research Triangle Park, NC 27709 | P.919.328.4400 | F.919.328.4402 | email: info@liquidia.com